BR112012013049A2 - potencializador do efeito antitumor. - Google Patents

potencializador do efeito antitumor.

Info

Publication number
BR112012013049A2
BR112012013049A2 BR112012013049A BR112012013049A BR112012013049A2 BR 112012013049 A2 BR112012013049 A2 BR 112012013049A2 BR 112012013049 A BR112012013049 A BR 112012013049A BR 112012013049 A BR112012013049 A BR 112012013049A BR 112012013049 A2 BR112012013049 A2 BR 112012013049A2
Authority
BR
Brazil
Prior art keywords
group
antitumor effect
alkyl
agent
enhancer
Prior art date
Application number
BR112012013049A
Other languages
English (en)
Inventor
Hitoshi Miyakoshi
Junko Taguchi
Masayoshi Fukuoka
Seiji Miyahara
Tatsushi Yokogawa
Wakako Yano
Yayoi Takao
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of BR112012013049A2 publication Critical patent/BR112012013049A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

potencializado do efeito antitumor - é fornecido um agente para potencializar os efeitos de um agente antitumor. um potencializador do efeito antitumor contendo, como um ingrediente ativo, um composto de uracila representado pela seguinte fórmula (i) ou um sal farmaceuticamente aceitável do mesmo: em que x representa um grupo c ~1-5~ alquileno e um dentre grupos metileno constituindo o grupo alquileno é opcionalmente substituído com um átomo de oxigênio; r ^1^ representa um átomo de hidrogênio ou um grupo c ~1-6~ alquia, um grupo c ~2-6~ cicloalquila, um grupo (c ~3-6 ~ cicloalquil) c ~1-6~ alquia, um grupo halogênio-c ~1-6 ~ alquila ou um grupo heterocíclico saturado.
BR112012013049A 2009-11-30 2010-11-29 potencializador do efeito antitumor. BR112012013049A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009272738 2009-11-30
PCT/JP2010/071280 WO2011065541A1 (ja) 2009-11-30 2010-11-29 抗腫瘍効果増強剤

Publications (1)

Publication Number Publication Date
BR112012013049A2 true BR112012013049A2 (pt) 2016-11-22

Family

ID=44066645

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012013049A BR112012013049A2 (pt) 2009-11-30 2010-11-29 potencializador do efeito antitumor.

Country Status (15)

Country Link
US (1) US8883759B2 (pt)
EP (2) EP3673908B1 (pt)
JP (1) JP5336606B2 (pt)
KR (1) KR101701549B1 (pt)
CN (2) CN102612369B (pt)
AU (1) AU2010323454B2 (pt)
BR (1) BR112012013049A2 (pt)
CA (1) CA2782280C (pt)
ES (2) ES2906227T3 (pt)
HK (2) HK1171185A1 (pt)
MX (1) MX2012006183A (pt)
MY (1) MY161094A (pt)
RU (1) RU2548913C2 (pt)
TW (1) TWI466870B (pt)
WO (1) WO2011065541A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY149180A (en) * 2008-06-03 2013-07-31 Taiho Pharmaceutical Co Ltd Uracil compound having inhibitor activity on human deoxyuridine triphosphatase or salt thereof
MY161094A (en) 2009-11-30 2017-04-14 Taiho Pharmaceutical Co Ltd Anti-tumor effect potentiator
CN105189478B (zh) * 2013-01-07 2019-10-22 南加州大学 脱氧尿苷三磷酸酶抑制剂
US9790214B2 (en) 2014-01-03 2017-10-17 University Of Southern California Heteroatom containing deoxyuridine triphosphatase inhibitors
US20180110780A1 (en) * 2015-04-30 2018-04-26 Taiho Pharmaceutical Co., Ltd. Agent for alleviating side effect of antitumor drug
BR112017023649A2 (pt) 2015-05-01 2018-07-17 Taiho Pharmaceutical Co., Ltd. novo cristal de composto de uracila
US10570100B2 (en) 2015-07-08 2020-02-25 University Of Southern California Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage
EA037990B1 (ru) 2015-07-08 2021-06-21 Св6 Терапьютикс (Най) Лимитед Ингибиторы дезоксиуридинтрифосфатазы, содержащие гидантоин
US10544105B2 (en) 2015-07-08 2020-01-28 Cv6 Therapeutics (Ni) Limited Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
WO2017006270A1 (en) 2015-07-08 2017-01-12 University Of Southern California Deoxyuridine triphosphatase inhibitors
CN106692173A (zh) * 2015-11-18 2017-05-24 北京诺普德医药科技有限公司 一种抗肿瘤复方组合物及其应用
MA43590A (fr) * 2016-01-08 2018-11-14 Taiho Pharmaceutical Co Ltd Agent antitumoral contenant un immunomodulateur et un amplificateur d'effet antitumoral
US11168059B2 (en) 2016-11-23 2021-11-09 Cv6 Therapeutics (Ni) Limited Amino sulfonyl compounds
WO2018098206A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US10829457B2 (en) 2016-11-23 2020-11-10 Cv6 Therapeutics (Ni) Limited Nitrogen ring linked deoxyuridine triphosphatase inhibitors
WO2018098204A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited 6-membered uracil isosteres
WO2018098207A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US11247984B2 (en) 2017-01-05 2022-02-15 Cv6 Therapeutics (Ni) Limited Uracil containing compounds
RU2706339C1 (ru) * 2019-07-24 2019-11-18 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ ИМЕНИ АКАДЕМИКА А.М. ГРАНОВА" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ / ФГБУ "РНЦРХТ им. ак. А.М. Гранова" Минздрава России Способ лечения операбельной аденокарциномы головки поджелудочной железы
JP2023040314A (ja) * 2020-02-18 2023-03-23 大鵬薬品工業株式会社 ウラシル誘導体化合物を含有する抗腫瘍効果増強剤
CN115843249A (zh) 2020-06-26 2023-03-24 Cv6治疗(Ni)有限公司 与脱氧尿苷三磷酸酶抑制剂联合治疗

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5839672A (ja) * 1981-09-03 1983-03-08 Chugai Pharmaceut Co Ltd ウラシル誘導体
JPH09286786A (ja) * 1996-04-18 1997-11-04 Nippon Paper Ind Co Ltd ピリミジン誘導体及びその抗腫瘍剤としての用途
RU2102390C1 (ru) * 1996-06-06 1998-01-20 Научно-исследовательская лаборатория иммунохимиотерапии лепры и иммунотропных средств с клиникой и опытно-экспериментальным производством МЗМП России N-(6-метил-2,4-диоксо-1,2,3,4-тетрагидропиримидинил-5-сульфонил) пиразин-2-карбоксамид, обладающий противолепрозной, противотуберкулезной и иммунотропной активностью, способ его получения
GB0400290D0 (en) * 2004-01-08 2004-02-11 Medivir Ab dUTPase inhibitors
EP1939186A1 (en) * 2006-12-22 2008-07-02 Sulfidris S.r.l. 5-Fluorouracil derivatives and their use for the treatment of cancer
MY149180A (en) * 2008-06-03 2013-07-31 Taiho Pharmaceutical Co Ltd Uracil compound having inhibitor activity on human deoxyuridine triphosphatase or salt thereof
JP2013032293A (ja) * 2009-11-30 2013-02-14 Taiho Yakuhin Kogyo Kk ヒトｄＵＴＰａｓｅ阻害活性を有する５−フルオロウラシル化合物又はその塩
MY161094A (en) 2009-11-30 2017-04-14 Taiho Pharmaceutical Co Ltd Anti-tumor effect potentiator
JP5839672B2 (ja) * 2011-09-28 2016-01-06 株式会社日立製作所 低真空軟ｘ線実験装置

Also Published As

Publication number Publication date
HK1195733A1 (zh) 2014-11-21
KR101701549B1 (ko) 2017-02-01
JP5336606B2 (ja) 2013-11-06
MY161094A (en) 2017-04-14
CN103948599A (zh) 2014-07-30
CN102612369B (zh) 2014-06-18
KR20120116925A (ko) 2012-10-23
HK1171185A1 (en) 2013-03-22
ES2788549T3 (es) 2020-10-21
AU2010323454A2 (en) 2012-06-14
WO2011065541A1 (ja) 2011-06-03
AU2010323454A1 (en) 2012-06-21
CA2782280C (en) 2019-02-26
TW201124387A (en) 2011-07-16
ES2906227T3 (es) 2022-04-13
RU2548913C2 (ru) 2015-04-20
US20120225838A1 (en) 2012-09-06
EP3673908A1 (en) 2020-07-01
JPWO2011065541A1 (ja) 2013-04-18
CA2782280A1 (en) 2011-06-03
EP2508185A1 (en) 2012-10-10
RU2012127309A (ru) 2014-01-10
TWI466870B (zh) 2015-01-01
EP2508185A4 (en) 2016-05-25
CN102612369A (zh) 2012-07-25
EP3673908B1 (en) 2022-01-12
AU2010323454B2 (en) 2014-05-08
US8883759B2 (en) 2014-11-11
MX2012006183A (es) 2012-06-19
CN103948599B (zh) 2016-03-09
EP2508185B1 (en) 2020-03-04

Similar Documents

Publication Publication Date Title
BR112012013049A2 (pt) potencializador do efeito antitumor.
UA112061C2 (uk) Активуючі ampk гетероциклічні сполуки і способи їх використання
BR112012026950A2 (pt) composto, e, uso de um composto
BR112015032921A8 (pt) compostos de benzofuranila e benzoxazolila substituídos e utilizações dos mesmos
BR112012003955A2 (pt) compostos heterocíclicos tricíclicos como inibidores da fosfoinositídeos 3-quinase
ATE542813T1 (de) 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
MX2015013051A (es) 1-hidroxi-benzooxaboroles como agentes antiparasitarios.
BR112013004818A2 (pt) "agente de controle de peste"
EA201591455A1 (ru) Производные бензимидазолона в качестве ингибиторов бромодомена
BR112014017749A8 (pt) Composto alquinilbenzeno 3,5-dissubstituído e sal do mesmo
SV2009003376A (es) Derivados de aril isoxazolinas insecticidas
BR112012027373A2 (pt) composição pesticida e seu uso
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
BR112013021941A2 (pt) agente terapêutico para tumor
RS54526B1 (en) USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS
EA200900924A1 (ru) Циклизованные производные как ингибиторы eg-5
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
TR201904327T4 (tr) Dimetilbenzoik asit bileşikleri.
MA38583B1 (fr) Dérivés de dolastatine 10 et d'auristatines
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
BR112012027378A2 (pt) composto pesticida e seu uso
BR112012027387A2 (pt) composição para controle de doenças de plantas e uso da mesma
TR201902057T4 (tr) Tetrasiklin bileşikleri.
BR112013010850A2 (pt) composto de etinilfenilamidina ou sal do mesmo, método para produzir o mesmo e fungicida para uso agrícola e em horticultura
RS53940B1 (en) HETEROARYL UNITS AS LIGANDS OF 5-HT4 RECEPTORS

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]